Browse the evidence

Liraglutide (1.8 mg) improves liver enzymes and reduces hepatic steatosis in MASH patients, though its ability to resolve NASH histology is modest compared to semaglutide.

Liraglutide 1.8 mg can significantly lower liver enzymes (ALT/AST) and reduce liver fat in MASH patients. However, it is less effective than semaglutide at fully resolving the inflammation (NASH) itself, so it may be a good option for enzyme control but less so for complete histological reversal.

GLP-1 receptor agonists (GLP-1RAs) reduce cardiovascular risk and body weight in obese patients with pre-existing cardiovascular disease, regardless of diabetes status, by modulating metabolic pathways, reducing inflammation, and slowing gastric emptying.

If you are overweight or obese and have existing heart disease, GLP-1 receptor agonists like semaglutide are a proven treatment to lower your risk of heart attacks, strokes, and death from heart causes, even if you don't have diabetes. These drugs work by mimicking a hormone that helps control blood sugar, reduces appetite, and slows digestion. While they are injections, their ability to protect your heart and reduce weight makes them a critical tool for secondary prevention. Always discuss with your doctor if this is right for you, especially regarding side effects and dosing.

Obesity pharmacotherapies, specifically high-dose semaglutide and tirzepatide, are highly effective for long-term weight management (>10% loss at 6 months) but remain dramatically underprescribed due to clinician knowledge gaps, safety concerns, and insurance coverage limitations.

If you qualify for obesity pharmacotherapy, discuss semaglutide or tirzepatide with your provider. While highly effective (>10% weight loss), access is limited by insurance. Ask about coverage options, especially if you have cardiovascular risk, as recent policy changes may improve access.

Obesity and metabolic disease are driven by a misalignment between behaviors (feeding/fasting rhythms, physical activity) and tissue functions (organ clocks), regulated by circadian molecular clocks in the brain and periphery.

Your body's organs operate on a 24-hour schedule. Try to align your eating and sleeping times with your natural circadian rhythm. Eating large meals late at night or irregularly can disrupt the internal clocks in your liver, muscle, and fat, leading to metabolic issues. Consistent meal times and adequate sleep support better metabolic health.

Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, produces significant weight loss and reduced hunger in patients with severe obesity linked to specific genetic deficiencies (POMC, PCSK1, LEPR, BBS, Alström, SRC1, SH2B1).

For individuals with severe obesity caused by specific genetic mutations (like POMC or LEPR deficiencies), Setmelanotide is a highly effective treatment that significantly reduces body weight and hunger. It requires regular injections, and patients should be prepared for common side effects like skin darkening and injection site reactions, which are generally manageable. This treatment is specifically indicated for genetic forms of obesity, not general weight loss.

Obesity exacerbates cardiovascular disease (CVD) risk and mortality through structural and metabolic mechanisms, including visceral fat deposition, pro-inflammatory cytokine release (TNF-α, IL-1, IL-6), and lipotoxicity from free fatty acids and ceramides.

Obesity is not just about weight; it is a state of chronic inflammation and metabolic signaling disruption that directly harms the heart and blood vessels. Managing obesity requires addressing these underlying biological mechanisms, such as reducing visceral fat and inflammation, to lower cardiovascular risk.

Activation of the AMPK pathway in adipocytes inhibits adipogenesis, enhances insulin sensitivity, promotes thermogenesis, and leads to weight loss, whereas activation in the central nervous system results in weight gain and increased appetite.

While activating AMPK in fat cells can help burn fat and improve insulin sensitivity, activating it in the brain can have the opposite effect, increasing appetite and weight gain. This highlights the complexity of targeting metabolic pathways.

Discontinuation of GLP-1 RA or GIP/GLP-1 RA therapy (liraglutide, semaglutide, tirzepatide) leads to rapid and substantial weight regain, effectively reversing the majority of metabolic benefits achieved during treatment.

If you stop taking GLP-1 or GIP/GLP-1 medications (like semaglutide or tirzepatide), you will likely regain most of the weight you lost. The drugs work by altering hormonal signals that regulate hunger and metabolism; when you stop, those signals revert. To maintain weight loss, you likely need to continue the medication long-term or adopt a rigorous, sustainable lifestyle intervention that mimics the drug's effects, though current evidence suggests pharmacological support is often necessary to prevent rebound.

Skeletal muscle mass loss with advancing age is primarily driven by anabolic resistance (blunted muscle protein synthesis response to protein and exercise) rather than increased protein breakdown, with losses accelerating after the 7th decade of life.

Focus on maintaining muscle mass through regular resistance exercise and adequate protein intake, especially as you enter your 60s and beyond. The rate of loss accelerates significantly after age 70, making early and consistent intervention critical to preserving independence and healthspan.

Muscle function (strength and power) declines at a substantially faster rate than muscle mass, with power loss beginning as early as young adulthood (20-39 years).

Prioritize power training (moving weight quickly) in addition to strength training. Since power loss starts in your 20s and 30s, maintaining explosive movement capability is key to preventing future frailty and falls.

Tirzepatide treatment in people with type 2 diabetes shifts body fat distribution toward a more balanced pattern by significantly reducing visceral adipose tissue (VAT) and liver fat (LF) while preserving abdominal subcutaneous adipose tissue (aSAT) relative to the amount of weight lost.

If you have type 2 diabetes and are prescribed tirzepatide, expect significant reductions in dangerous visceral and liver fat. Importantly, the drug appears to preserve your subcutaneous fat (the fat under the skin) better than other weight-loss methods might, leading to a healthier overall fat distribution pattern. This shift occurs alongside weight loss and improves cardiometabolic risk markers.

Delayed gastric emptying contributes to weight loss with GLP-1 agonists, but central appetite suppression is the predominant mechanism.

While GLP-1 drugs slow stomach emptying, this only explains about 20% of the weight loss. The main driver is reduced hunger and food intake due to brain signaling.

Semaglutide (2.4 mg/week) provides significantly better economic value for weight reduction than liraglutide (3 mg/day), with a lower cost needed to treat per 1% body weight reduction.

If you are choosing between semaglutide and liraglutide for weight loss in the US, semaglutide is the more economically efficient option. It achieves nearly double the weight loss (12.4% vs 5.4%) for a lower cost per percentage point of weight lost, despite having a higher total therapy cost. The weekly injection schedule may also improve convenience and adherence compared to daily injections.

Baseline Respiratory Quotient (RQ) can predict which diet (Low-Carb or Low-Fat) will be more effective for an individual's short-term weight loss.

If you can measure your baseline Respiratory Quotient (RQ), a high RQ suggests you might lose more weight on a Low-Carb diet, while a low RQ might suggest a Low-Fat diet could be more effective.

GLP-1-based therapies (liraglutide, semaglutide, tirzepatide) reduce blood pressure in individuals with overweight or obesity, with tirzepatide demonstrating the greatest magnitude of reduction.

If you have high blood pressure and carry extra weight, GLP-1 medications like semaglutide or tirzepatide can lower your blood pressure, sometimes allowing you to take fewer other blood pressure pills. Tirzepatide appears to lower blood pressure more than other options in this class. These are weekly injections, which might be easier to manage than daily pills, though they can cause stomach side effects.

Transitioning from a very-low-carbohydrate diet to a high-carbohydrate diet requires several weeks (approximately 5-9 weeks) for full glycemic adaptation, meaning a 3-day preparation period is insufficient for accurate diabetes screening in habitual low-carb dieters.

If you have been eating a very low-carb diet and plan to switch to a higher-carb diet (or undergo a diabetes test), do not expect your blood sugar to stabilize immediately. It can take 5 to 9 weeks for your body to fully adapt to processing carbohydrates again. If you are getting a diabetes screening, inform your doctor about your recent low-carb diet history, as a standard 3-day prep may yield a false positive.

Dual GIP and GLP-1 receptor agonist tirzepatide significantly improves kidney outcomes in adults with type 2 diabetes and increased cardiovascular risk compared to insulin.

If you have Type 2 Diabetes and are at risk for kidney disease, ask your doctor about tirzepatide. It is a once-weekly injection that has been shown to significantly reduce the risk of serious kidney problems compared to insulin, while also helping with blood sugar and weight control. You do not need to adjust the dose even if you have kidney disease.

GLP-1 receptor agonists (specifically tirzepatide and liraglutide) significantly reduce Obstructive Sleep Apnea (OSA) severity, measured by Apnea-Hypopnea Index (AHI), primarily through substantial weight loss, while also providing independent cardiovascular benefits such as reduced vascular inflammation and improved endothelial function.

If you have OSA and obesity, GLP-1 agonists like tirzepatide or liraglutide can significantly reduce your sleep apnea severity (AHI) and improve cardiovascular health, largely by helping you lose weight. While CPAP is still the gold standard for mechanically opening the airway, GLP-1s offer a pharmacological option that also targets inflammation and blood pressure. Expect weekly injections and potential gastrointestinal side effects, which may affect adherence. Discuss with your doctor if you are a candidate, especially if you have Type 2 Diabetes.

GLP-1 receptor agonists (specifically Liraglutide and Semaglutide) promote NASH resolution and reduce hepatic steatosis in patients with T2DM and NAFLD, primarily through weight loss and reduced de novo lipogenesis.

If lifestyle changes alone aren't enough to manage your fatty liver and diabetes, ask your doctor about GLP-1 medications like Liraglutide or Semaglutide. These drugs have been shown to significantly improve liver inflammation and fat content, with Semaglutide showing high rates of NASH resolution. They work by mimicking a gut hormone that helps regulate blood sugar and liver fat production.

Pioglitazone improves NASH resolution and fibrosis stages in patients with T2DM and NAFLD, but its use is limited by side effects such as weight gain and bone fracture risk.

Pioglitazone is a diabetes medication that can also improve liver inflammation and fibrosis in fatty liver disease. However, it can cause weight gain, swelling, and increase the risk of bone fractures. It is generally used when other treatments are not suitable or effective, and the benefits for the liver must be weighed against these risks.

Maintaining lower HbA1c levels (<7%) is associated with slower progression of biological aging, as measured by the deficit accumulation frailty index, over an 8-year period in adults with type 2 diabetes.

If you have type 2 diabetes, keeping your average blood sugar (HbA1c) below 7% is linked to slower biological aging and less physical decline over time compared to higher levels. Work with your doctor to achieve this target safely, as it appears to protect your long-term health.

Consistent use of metformin (≥50% of assessments) is independently associated with slower progression of the frailty index in adults with type 2 diabetes, after adjusting for HbA1c and weight loss.

Taking metformin consistently is linked to slower physical decline in people with type 2 diabetes, even after accounting for weight loss and blood sugar levels. Discuss with your doctor if metformin is the right long-term strategy for you.

A lower n-6 to n-3 PUFA ratio (e.g., 5:1) shifts eicosanoid production toward anti-inflammatory mediators (resolvins, protectins), reducing cardiovascular disease risk, whereas the Western diet's high n-6/n-3 ratio promotes inflammation and atherosclerosis.

To reduce cardiovascular risk, aim to lower your intake of omega-6 fatty acids (common in vegetable oils) relative to omega-3s (from fish or algae). A ratio closer to 5:1 or lower is associated with less inflammation and lower CVD risk compared to the typical Western diet ratio.

Modulating the gut microbiome and its metabolites through diet, pharmaceuticals (e.g., GLP-1 agonists, SGLT2 inhibitors), or microbiota therapies (e.g., probiotics, FMT) improves glycemic control and ameliorates Type 2 Diabetes complications by influencing pancreatic islet function, hepatic metabolism, and systemic inflammation.

To leverage the gut-diabetes connection, prioritize high-fiber diets to boost beneficial bacteria that produce short-chain fatty acids (SCFAs) and GLP-1. If lifestyle changes are insufficient, discuss GLP-1 receptor agonists (like semaglutide) or dual agonists (like tirzepatide) with your doctor, as these medications directly exploit the gut-pancreas axis to lower blood sugar and promote weight loss. Probiotics (specifically strains like Akkermansia muciniphila) may offer modest additional benefits, but they are not a replacement for core therapies.